-
目前, 临床上评价肿瘤治疗疗效仍是通过测量治疗前后肿瘤体积变化的方法。参考世界卫生组织公布的实体瘤治疗反应评价标准, 影像学上当肿瘤在最大长径上减少30%即判断为有反应[5]。但由于此标准存在前述缺陷, 其临床应用也受到一些限制。尽管PET显示出一些独特的优势, 但其评价疗效的标准在实践中仍存在争议。2009年PET监测实体肿瘤疗效的标准总则草案已公布, 建议使用SUV降低率的阈值作为判断标准, 总体推荐SUV降低率>30%提示反应良好, 具体见表 1[6]。
判断标准 完全代谢反应 靶区18F-FDG摄取完全减退至低于肝脏内活性水平 部分代谢反应 靶区18F-FDG SUL峰值降低≥30%, 且SUL下降的绝对值≥0.8 SUL单位 疾病代谢稳定 非完全代谢反应、部分代谢反应或疾病代谢进展 疾病代谢进展 靶区18F-FDG SUL峰值升高 > 30%, 且肿瘤SUV峰值比基线增加 > 0.8 SUL单位(不含由感染或治疗带来的效应) 注:表中,PERCIST:PET监测实体肿瘤疗效的标准总则;SUL:用去脂体重标化的标准化摄取值。 表 1 PET评价肿瘤治疗疗效的PERCIST标准
18F-FDG PET用于肿瘤治疗疗效评价的meta分析进展
Tumor response monitoring by 18F-FDG PET:updated review of meta-analyses
-
摘要: 目前, 大部分抗肿瘤治疗只在某些患者亚组中有效, 对肿瘤治疗疗效的个体化监测的需求日益突出。传统解剖显像用于肿瘤治疗疗效的评价尚存在一些缺陷, 而18F-FDG PET在肿瘤中的临床应用及其meta分析等统计学证据不断增多, 该文将对其监测多种肿瘤的治疗疗效的应用情况进行综合性的回顾。基于PET能早期显示肿瘤的代谢特征, 比传统解剖显像具有独特的优势, 多项meta分析结果显示其用于疗效评价的准确率普遍较高。在某些肿瘤如淋巴瘤中, PET因其较高的灵敏度和特异度, 已写入新的国际诊疗指南; 而在其他多种肿瘤如非小细胞肺癌、乳腺癌、食管癌、胃食管交界处腺癌、直肠癌、胃肠道间质瘤等中, PET仍存在缺乏临床标准方案、各研究结果间异质性大等问题。此外, PET检查结果中还存在一定的假阳性和假阴性, 在临床应用中需分析原因, 提高警惕。因此, 今后仍需要更多大样本的前瞻性、随机化实验来充分验证PET在肿瘤治疗疗效评价中的地位。
-
关键词:
- 肿瘤 /
- 治疗结果 /
- Meta分析 /
- 氟脱氧葡萄糖F18 /
- 正电子发射断层显像术
Abstract: Most anticancer drugs are effective only in subgroups of patients, which makes the individualization of tumor response monitoring quite in need. Since the current anatomic imaging has certain limitations for this utility, and the clinical evidence of 18F-FDG PET from meta-analysis is increasing, this study gives a comprehensive review of the performance of PET in monitoring response of a variety of tumors. Given the early metabolic characterization of tumors by PET, this technology exhibited special advantages to traditional imaging modalities and generally yielded high accuracies in tumor response assessment in many meta-analyses. In certain type of tumors as malignant lymphoma, PET has recently been placed to a central role in defining tumor response in international criteria. In other tumors as non-small cell lung cancer, breast cancer, esophageal cancer, adenocarcinomas of the esophagogastric junction, rectal cancer and gastrointestinal stromal tumor, questions remain due to lack of standard regimen of PET and heterogeneity between individual study results. Besides, certain numbers of false positive and false negative results of PET still call for caution in clinical scenarios. More prospective and large sampled random trials are warranted to fully validate and position PET in tumor management.-
Key words:
- Neoplasms /
- Treatment outcome /
- Meta-analysis /
- Fluorodeoxyglucose F18 /
- Positron emission tomography
-
表 1 PET评价肿瘤治疗疗效的PERCIST标准
判断标准 完全代谢反应 靶区18F-FDG摄取完全减退至低于肝脏内活性水平 部分代谢反应 靶区18F-FDG SUL峰值降低≥30%, 且SUL下降的绝对值≥0.8 SUL单位 疾病代谢稳定 非完全代谢反应、部分代谢反应或疾病代谢进展 疾病代谢进展 靶区18F-FDG SUL峰值升高 > 30%, 且肿瘤SUV峰值比基线增加 > 0.8 SUL单位(不含由感染或治疗带来的效应) 注:表中,PERCIST:PET监测实体肿瘤疗效的标准总则;SUL:用去脂体重标化的标准化摄取值。 -
[1] Strauss GM, Herndon JE 2nd, Maddaus MA, et al. Adjuvant pacli-taxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer:CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group study groups. J Clin Oncol, 2008, 26(31):5043-5051. doi: 10.1200/JCO.2008.16.4855 [2] Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evalua-tion criteria in solid tumours:revised RECIST guideline(version 1. 1). Eur J Cancer, 2009, 45(2):228-247. doi: 10.1016/j.ejca.2008.10.026 [3] Weber WA. Assessing tumor response to therapy. J Nucl Med, 2009, 50 Suppl1:1S-10. [4] Hillner BE, Siegel BA, Liu D, et al. Impact of positron emission tomography/computed tomography and positron emission tomography(PET) alone on expected management of patients with cancer:initial results from the National Oncologic PET Registry. J Clin Oncol, 2008, 26(13):2155-2161. doi: 10.1200/JCO.2007.14.5631 [5] Therasse P, Eisenhauer EA, Verweij J. RECIST revisited:a review of validation studies on tumour assessment. Eur J Cancer, 2006, 42(8):1031-1039. doi: 10.1016/j.ejca.2006.01.026 [6] Wahl RL, Jacene H, Kasamon Y, et al. From RECIST to PERCIST:evolving considerations for PET response criteria in solid tumors. J Nucl Med, 2009, 50 Suppl1:122S-150. [7] Hutchings M, Barrington SF. PET/CT for therapy response assess-ment in lymphoma. J Nucl Med, 2009, 50 Suppl1:21S-30. [8] Zinzani PL, Gandolfi L, Broccoli A, et al. Midtreatment 18F-fluo-rodeoxyglucose positron-emission tomography in aggressive non-Hodgkin lymphoma. Cancer, 2011, 117(5):1010-1018. doi: 10.1002/cncr.25579 [9] Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol, 2007, 25(5):579-586. doi: 10.1200/JCO.2006.09.2403 [10] Ramos-Font C, Rebollo Aguirre AC, Villegas Portero R, et al. 18F-fluorodeoxyglucose positron emission tomography in the evaluation of therapy response assessment in lymphomas. Systematic literature review and meta-analysis. Rev Esp Med Nucl, 2009, 28(2):48-55. doi: 10.1016/S0212-6982(09)70696-2 [11] Zijlstra JM, Lindauer-van der Werf G, Hoekstra OS, et al. 18F-fluoro-deoxyglucose positron emission tomography for post-treatment evaluation of malignant lymphoma:a systematic review. Haemato-logica, 2006, 91(4):522-529. [12] Terasawa T, Nihashi T, Hotta T, et al. 18F-FDG PET for posttherapy assessment of Hodgkin's disease and aggressive Non-Hodgkin's lymphoma:a systematic review. J Nucl Med, 2008, 49(1):13-21. [13] Terasawa T, Dahabreh IJ, Nihashi T. Fluorine-18-fluorodeoxyglu-cose positron emission tomography in response assessment before high-dose chemotherapy for lymphoma:a systematic review and meta-analysis. Oncologist, 2010, 15(7):750-759. doi: 10.1634/theoncologist.2010-0054 [14] Rebollo-Aguirre AC, Ramos-Font C, Villegas Portero R, et al. Is FDG-PET suitable for evaluating neoadjuvant therapy in non-small cell lung cancer? Evidence with systematic review of the literature. J Surg Oncol, 2010, 101(6):486-494. doi: 10.1002/jso.21525 [15] Avril N, Sassen S, Roylance R. Response to therapy in breast cancer. J Nucl Med, 2009, 50 Suppl1:55S-63. [16] Wang Y, Zhang C, Liu J, et al. Is 18F-FDG PET accurate to predict neoadjuvant therapy response in breast cancer? A meta-analysis. Breast Cancer Res Treat, 2012, 131(2):357-369. doi: 10.1007/s10549-011-1780-z [17] Cheng X, Li Y, Liu B, et al. 18F-FDG PET/CT and PET for evaluation of pathological response to neoadjuvant chemotherapy in breast cancer:a meta-analysis. Acta Radiol, 2012, 53(6):615-627. doi: 10.1258/ar.2012.110603 [18] Graham AJ, Shrive FM, Ghali WA, et al. Defining the optimal treat-ment of locally advanced esophageal cancer:a systematic review and decision analysis. Ann Thorac Surg, 2007, 83(4):1257-1264. doi: 10.1016/j.athoracsur.2006.11.061 [19] Rebollo Aguirre AC, Ramos-Font C, Villegas Portero R, et al. 18F-fluorodeoxiglucose positron emission tomography for the evaluation of neoadjuvant therapy response in esophageal cancer:systematic review of the literature. Ann Surg, 2009, 250(2):247-254. doi: 10.1097/SLA.0b013e3181b0c3a6 [20] Westerterp M, van Westreenen HL, Reitsma JB, et al. Esophageal cancer:CT, endoscopic US, and FDG PET for assessment of response to neoadjuvant therapy—systematic review. Radiology, 2005, 236(3):841-851. [21] Yanagawa M, Tatsumi M, Miyata H, et al. Evaluation of response to neoadjuvant chemotherapy for esophageal cancer:PET response criteria in solid tumors versus response evaluation criteria in solid tumors. J Nucl Med, 2012, 53(6):872-880. doi: 10.2967/jnumed.111.098699 [22] Suttie SA, Welch AE, Park KG. Positron emission tomography for monitoring response to neoadjuvant therapy in patients with oesophageal and gastro-oesophageal junction carcinoma. Eur J Surg Oncol, 2009, 35(10):1019-1029. doi: 10.1016/j.ejso.2009.01.012 [23] Neuman HB, Elkin EB, Guillem JG, et al. Treatment for patients with rectal cancer and a clinical complete response to neoadjuvant therapy:a decision analysis. Dis Colon Rectum, 2009, 52(5):863-871. doi: 10.1007/DCR.0b013e31819eefba [24] Zhang C, Tong J, Sun X, et al. 18F-FDG-PET evaluation of treatment response to neo-adjuvant therapy in patients with locally advanced rectal cancer:a meta-analysis. Int J Cancer, 2012, 131(11):2604-2611. doi: 10.1002/ijc.27557 [25] Young H, Baum R, Cremerius U, et al. Measurement of clinical and subclinical tumour response using[18F]-fluorodeoxyglucose and positron emission tomography:review and 1999 EORTC recom-mendations. European Organization for Research and Treatment of Cancer(EORTC) PET Study Group. Eur J Cancer, 1999, 35(13):1773-1782. doi: 10.1016/S0959-8049(99)00229-4 [26] Treglia G, Mirk P, Stefanelli A, et al. 18F-Fluorodeoxyglucose positron emission tomography in evaluating treatment response to imatinib or other drugs in gastrointestinal stromal tumors:a sys-tematic review. Clin Imaging, 2012, 36(3):167-175. doi: 10.1016/j.clinimag.2011.08.012 [27] Dose-Schwarz J, Tiling R, Avril-Sassen S, et al. Assessment of residual tumour by FDG-PET:conventional imaging and clinical examination following primary chemotherapy of large and locally advanced breast cancer. Br J Cancer, 2010, 102(1):35-41. doi: 10.1038/sj.bjc.6605427 [28] Park JS, Moon WK, Lyou CY, et al. The assessment of breast cancer response to neoadjuvant chemotherapy:comparison of magnetic resonance imaging and 18F-fluorodeoxyglucose positron emission tomography. Acta Radiol, 2011, 52(1):21-28.